Low-fat oxidation may be a factor in obesity among men with schizophrenia

J. K. Sharpe, T. J. Stedman, N. M. Byrne, A. P. Hills

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

Objective: Obesity associated with atypical antipsychotic medications is an important clinical issue for people with schizophrenia. The purpose of this project was to determine whether there were any differences in resting energy expenditure (REE) and respiratory quotient (RQ) between men with schizophrenia and controls. Method: Thirty-one men with schizophrenia were individually matched for age and relative body weight with healthy, sedentary controls. Deuterium dilution was used to determine total body water and subsequently fat-free mass (FFM). Indirect calorimetry using a Deltatrac metabolic cart was used to determine REE and RQ. Results: When corrected for FFM, there was no significant difference in REE between the groups. However, fasting RQ was significantly higher in the men with schizophrenia than the controls. Conclusion: Men with schizophrenia oxidised proportionally less fat and more carbohydrate under resting conditions than healthy controls. These differences in substrate utilisation at rest may be an important consideration in obesity in this clinical group.

Original languageEnglish
Pages (from-to)451-456
Number of pages6
JournalActa Psychiatrica Scandinavica
Volume119
Issue number6
DOIs
Publication statusPublished - Jun 2009
Externally publishedYes

Fingerprint

Schizophrenia
Obesity
Fats
Energy Metabolism
Indirect Calorimetry
Body Water
Deuterium
Antipsychotic Agents
Fasting
Body Weight
Carbohydrates

Cite this

Sharpe, J. K. ; Stedman, T. J. ; Byrne, N. M. ; Hills, A. P. / Low-fat oxidation may be a factor in obesity among men with schizophrenia. In: Acta Psychiatrica Scandinavica. 2009 ; Vol. 119, No. 6. pp. 451-456.
@article{340e49cc7a494686a092b2066b8e135a,
title = "Low-fat oxidation may be a factor in obesity among men with schizophrenia",
abstract = "Objective: Obesity associated with atypical antipsychotic medications is an important clinical issue for people with schizophrenia. The purpose of this project was to determine whether there were any differences in resting energy expenditure (REE) and respiratory quotient (RQ) between men with schizophrenia and controls. Method: Thirty-one men with schizophrenia were individually matched for age and relative body weight with healthy, sedentary controls. Deuterium dilution was used to determine total body water and subsequently fat-free mass (FFM). Indirect calorimetry using a Deltatrac metabolic cart was used to determine REE and RQ. Results: When corrected for FFM, there was no significant difference in REE between the groups. However, fasting RQ was significantly higher in the men with schizophrenia than the controls. Conclusion: Men with schizophrenia oxidised proportionally less fat and more carbohydrate under resting conditions than healthy controls. These differences in substrate utilisation at rest may be an important consideration in obesity in this clinical group.",
author = "Sharpe, {J. K.} and Stedman, {T. J.} and Byrne, {N. M.} and Hills, {A. P.}",
year = "2009",
month = "6",
doi = "10.1111/j.1600-0447.2008.01342.x",
language = "English",
volume = "119",
pages = "451--456",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "Wiley-Blackwell",
number = "6",

}

Low-fat oxidation may be a factor in obesity among men with schizophrenia. / Sharpe, J. K.; Stedman, T. J.; Byrne, N. M.; Hills, A. P.

In: Acta Psychiatrica Scandinavica, Vol. 119, No. 6, 06.2009, p. 451-456.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Low-fat oxidation may be a factor in obesity among men with schizophrenia

AU - Sharpe, J. K.

AU - Stedman, T. J.

AU - Byrne, N. M.

AU - Hills, A. P.

PY - 2009/6

Y1 - 2009/6

N2 - Objective: Obesity associated with atypical antipsychotic medications is an important clinical issue for people with schizophrenia. The purpose of this project was to determine whether there were any differences in resting energy expenditure (REE) and respiratory quotient (RQ) between men with schizophrenia and controls. Method: Thirty-one men with schizophrenia were individually matched for age and relative body weight with healthy, sedentary controls. Deuterium dilution was used to determine total body water and subsequently fat-free mass (FFM). Indirect calorimetry using a Deltatrac metabolic cart was used to determine REE and RQ. Results: When corrected for FFM, there was no significant difference in REE between the groups. However, fasting RQ was significantly higher in the men with schizophrenia than the controls. Conclusion: Men with schizophrenia oxidised proportionally less fat and more carbohydrate under resting conditions than healthy controls. These differences in substrate utilisation at rest may be an important consideration in obesity in this clinical group.

AB - Objective: Obesity associated with atypical antipsychotic medications is an important clinical issue for people with schizophrenia. The purpose of this project was to determine whether there were any differences in resting energy expenditure (REE) and respiratory quotient (RQ) between men with schizophrenia and controls. Method: Thirty-one men with schizophrenia were individually matched for age and relative body weight with healthy, sedentary controls. Deuterium dilution was used to determine total body water and subsequently fat-free mass (FFM). Indirect calorimetry using a Deltatrac metabolic cart was used to determine REE and RQ. Results: When corrected for FFM, there was no significant difference in REE between the groups. However, fasting RQ was significantly higher in the men with schizophrenia than the controls. Conclusion: Men with schizophrenia oxidised proportionally less fat and more carbohydrate under resting conditions than healthy controls. These differences in substrate utilisation at rest may be an important consideration in obesity in this clinical group.

UR - http://www.scopus.com/inward/record.url?scp=65749106937&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0447.2008.01342.x

DO - 10.1111/j.1600-0447.2008.01342.x

M3 - Article

VL - 119

SP - 451

EP - 456

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

SN - 0001-690X

IS - 6

ER -